Sectors
Boston-based startup General Prognostics is developing a digital biomarker platform for heart disease patients. It is one of a growing number of emerging blood-related tech startup raising funding.
Sanofi's strategic investment arm received a top up from its pharmceutical parent in a week when it led an $80m round for its latest portfolio company.
What's going to happen to healthcare startup funding this year? Will the IPO market recover? And what kinds of technologies are on the up? We asked some leading CVCs for their view.
The $275m round, the largest series B for three months, featured several pharmaceutical companies and is part of a thriving environment for gene therapy startups.
Aleks Engel, a Novo partner and Repair Impact Fund director, will work with the firm’s bioindustrial team to accelerate sustainability.
Take time, focus on quality and internal relationships, make an impact — these are the top resolutions investors have for 2023.
2022 saw a screeching turnaround in market sentiment. How well did corporate investors cope?
Corporate investors are backing a host of elder-care startups, from those seeking Parkinson's cures to apps aiding mental wellbeing.
A Japan-based university spinout is exploring a sound and touch treatment for dementia.
The cancer drug developer popped after an upsized offering, allowing Alexandria Venture Investments to exit and showing the IPO market is still breathing in the US.
The UK health insurer says it is a good time to launch a fund as the froth has come out of valuations and "sensible" money can go in.
NCSoft invested $15m in Mysten Labs to take the latter’s series B round to $300m while Porsche backed Xanadu’s $100m series C.
Suzano and Yara participated in Agrolend’s $145m latest round while Xencor contributed to Zenas BioPharma’s $118m series B.
Xiaomi provided $68.9m in series C funding for Atech Automotive while Intel and Micron were part of Eliyan’s $40m series A round.
What's going to happen to healthcare startup funding this year? Will the IPO market recover? And what kinds of technologies are on the up? We asked some leading CVCs for their view.
The $275m round, the largest series B for three months, featured several pharmaceutical companies and is part of a thriving environment for gene therapy startups.
Take time, focus on quality and internal relationships, make an impact — these are the top resolutions investors have for 2023.
Corporate investors are backing a host of elder-care startups, from those seeking Parkinson's cures to apps aiding mental wellbeing.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
